BMS-502, a novel dual DGK α and ζ inhibitor with promising immunostimulant activity
Aug. 11, 2023
Researchers from Bristol Myers Squibb Co. presented the discovery and preclinical evaluation of a novel diacylglycerol kinases (DGK) α and ζ dual inhibitors.